Additional Positive Interim Data from Phase I/II/III CAMPSIITE™ Trial of REGENXBIO's RGX-121 for the Treatment of MPS II (Hunter Syndrome) Presented at 19th Annual WORLDSymposiumTM

RGX-121, a potential one-time gene therapy for the treatment of MPS II, continues to be well-tolerated with no drug-related SAEs across three dose levels...

Related Keywords

United States ,Canada ,Brazil ,Dana Cormack ,Chris Brinzey ,Steve Pakola ,Toddler Development ,Technology Platform ,Technology Platform Licensees ,Drug Administration ,Perelman School Of Medicine ,Nasdaq ,Exchange Commission ,Corporate Communications ,University Of Pennsylvania ,Securities Exchange ,Biologics License Application ,Mucopolysaccharidosis Type ,Chief Medical Officer ,Can Ficicioglu ,Perelman School ,Safety Update ,Bayley Scales ,Vineland Adaptive Behavior Scales Second Edition ,Fast Track ,Hunter Syndrome ,Platform Licensees ,Securities Act ,Securities Exchange Act ,Financial Condition ,Regenxbio Inc ,